Business Wire

Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

Share

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.

“Patients with EGFR Exon20 insertion+ mNSCLC have no proven targeted therapy options,” said Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University. “The updated results from the Phase 1/2 study of mobocertinib demonstrate an encouraging objective response rate, duration of response and overall survival in patients who have received prior platinum-based chemotherapy.”

The analysis from the Phase 1/2 trial included patients with EGFR Exon20 insertion+ mNSCLC who received prior platinum-based chemotherapy. All patients were treated at the 160 mg once daily oral dose. Building on the findings presented in January at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC), results showed a median overall survival (OS) of 24 months with a median follow up of 14 months, and responses were observed across diverse EGFR Exon20 insertion variants. Other key data points remained consistent with previously reported data, including a confirmed objective response rate (ORR) of 28%, a median duration of response (DoR) of 17.5 months and a disease control rate (DCR) of 78% per independent review committee (IRC).

The safety profile observed was manageable and consistent with previous findings. The most common treatment-related adverse events (TRAEs; ≥ 20%) in platinum-pretreated patients from the updated data were diarrhea (91%), rash (45%), paronychia (38%), decreased appetite (35%), nausea (34%), dry skin (31%) and vomiting (30%). The only Grade ≥3 TRAE (≥5%) was diarrhea (21%). AEs leading to discontinuation in >2% were diarrhea (4%) and nausea (4%).

“We are excited to add this promising overall survival data to the body of evidence demonstrating mobocertinib’s potential as an effective oral treatment option for platinum-pretreated patients with EGFR Exon20 insertion+ mNSCLC,” said Christopher Arendt, PhD, Head, Oncology Therapeutic Area Unit, Takeda. “Mobocertinib is currently undergoing priority review with the U.S. FDA, and we look forward to continuing conversations with regulatory agencies around the world to introduce mobocertinib as a new treatment option for these patients.”

The FDA previously granted mobocertinib Breakthrough Therapy Designation in April 2020 and priority review for the New Drug Application (NDA) in April 2021. If approved, mobocertinib will be the first oral therapy available that is specifically designed to selectively target EGFR Exon20 insertion mutations.

Takeda has established an Expanded Access Program (EAP) for patients who may be eligible to receive access to mobocertinib while this investigational therapy is under review by regulatory authorities. Additional information, including the specific conditions to qualify for Takeda’s EAP, is available here.

Learn more about Takeda Oncology’s presence at this year’s ASCO Annual Meeting. Takeda will host a webcast for analysts and investors on Tuesday, June 8, at 6:30 p.m. ET to discuss these and other data being presented at ASCO and to provide an update on the oncology pipeline. Please contact TakedaRandDEvents@fticonsulting.com for further details. Presentation slides and an archived replay of the webcast will be available at https://www.takeda.com/investors/reports/ir-events/.

About Mobocertinib (TAK-788)

Mobocertinib is an investigational, first-in-class, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) Exon20 insertion mutations. In 2019, the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations. In April 2020, mobocertinib received Breakthrough Therapy Designation from the FDA for patients with EGFR Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) whose disease has progressed on or after platinum-based chemotherapy. In October 2020, mobocertinib was designated as a Breakthrough Therapy in China by the Center for Drug Evaluation (CDE) for locally advanced or metastatic NSCLC patients with EGFR Exon20 insertion mutations who have been previously treated with at least one prior systemic chemotherapy.

About the Phase 1/2 Trial

The Phase 1/2 trial evaluated the safety, pharmacokinetics and anti-tumor activity of oral mobocertinib in patients with non-small cell lung cancer (NSCLC). The trial is comprised of a Phase 1 dose-escalation, which evaluated mobocertinib as a monotherapy and in combination with chemotherapy, several expansion cohorts and an extension cohort in patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC).

The platinum-pretreated population efficacy analysis investigated 114 patients with EGFR Exon20 insertion+ mNSCLC who received prior platinum-based therapy in the Phase 1/2 trial and were treated with mobocertinib at the 160 mg once daily dose.

About EGFR Exon20 Insertion+ mNSCLC

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 1.8 million new cases of lung cancer diagnosed each year worldwide, according to the World Health Organization.1,2 Patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC) make up approximately 1-2% of patients with NSCLC, and the disease is more common in Asian populations compared to Western populations.3-7 This disease carries a worse prognosis than other EGFR mutations because there are currently no FDA-approved therapies that target EGFR Exon20 insertions, and current EGFR TKIs and chemotherapy provide limited benefit for these patients.

Takeda is committed to continuing research and development in EGFR Exon20 insertion+ mNSCLC with the hope of introducing a targeted treatment option for the approximately 30,000 patients diagnosed with the disease worldwide each year, including 3,000 in the U.S. alone.3,4

Takeda’s Commitment to Oncology

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”,

“should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

###

1 World Health Organization. Latest Global Cancer Data. https://www.who.int/cancer/PRGlobocanFinal.pdf. Accessed May 11, 2019.
2 American Cancer Society. What is Non-Small Cell Lung Cancer? https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html.
3 Riess, Jonathan W. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. https://www.jto.org/article/S1556-0864(18)30770-6/fulltext. Accessed April 7, 2020.
4 Fang, Wenfeng. BMC Cancer. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5820-0. Accessed April 7, 2020.
5 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179-1186. doi:10.1111/cas.12996
6 Yatabe Y, Kerr KM, Utomo A, et al. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol. 2015;10(3):438-445. doi:10.1097/JTO.0000000000000422
7 Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006. doi:10.1001/jama.2014.3741

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

Media Outside Japan
Lauren Padovan
lauren.padovan@takeda.com
+1 (617) 444-1419

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Smiths Medical Issues Worldwide Notification Regarding the Recall of Jelco ® Hypodermic Needle-Pro ® Fixed Needle Insulin Syringe With Skewed Graduation Markings16.6.2021 20:00:00 CEST | Press release

Smiths Medical has become aware of specific models and lots of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes that may exhibit skewed odd number line graduation markings on their syringe barrels. Markings skewed approximately 20 degrees upward have been identified. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005888/en/ Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes skewed graduation marking on the syringe barrel. (Photo: Business Wire) Affected Models and Lot Numbers: Model Number Name Lot Number 4428-1 Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 28Gx1/2” 1CC 4046543 and 4062235 4429-1 Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe 29Gx1/2” 1CC 4014096, 4031846, 4031845, 4040734, 4043536, 4046545, 4046546, 4062239, 4062240, 4062238 and 4062242 Please reference the attachment for an illustration of the skewed graduation marking on the syringe barrel. As a result of

Verimatrix Protects Recode Health’s STRIVE Benefits Mobile App16.6.2021 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced its application shielding solutions were selected by Oakland, California-based Recode Health to protect its STRIVE Benefits mobile app. Serving as the SaaS benefits communication platform of choice for thousands of businesses throughout the United States, STRIVE’s mobile app aims to modernize employer-employee relations by seamlessly educating employees so that they stay ahead of the curve and have fingertip access to their benefits guides, balances, financial information and other customizable data. Due to the sensitive nature of the information within the app, such as telemedicine and Rx integrations to save on healthcare costs, the STRIVE management team prioritizes its cybersecurity stance and looked to ensure that its mobile app is as secure as possible. “The protection of employer and employee data is paramount at STRIVE,

Biolog-id Partners With AirMed to Help Enhance Visibility, Availability, and Traceability of Life-saving Blood Components16.6.2021 17:18:00 CEST | Press release

Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with AirMed – one of the first air medical transport programs in the US. As part of this partnership, biolog-id’s cutting-edge technology will provide digital visibility to the inventory of red blood cells and liquid plasma across 5 locations in the state of Utah, covering one of the largest geographical areas in the nation, routinely transporting patients not only from Utah, but also from Colorado, Wyoming, Nevada, Montana, and Idaho. Biolog-id’s blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases. “We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation,” said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed. “We are committed to delivering the highest

Moody’s ESG Solutions Launches Bespoke Dataset to Help Market Participants Meet SFDR Requirements16.6.2021 17:10:00 CEST | Press release

Moody’s ESG Solutions today launched a bespoke ESG data solution to help market participants meet the European Union (EU) Sustainable Finance Disclosure Regulation (SFDR) requirements. Harnessing Moody’s ESG Solutions’ analytical rigor and advanced data capture processes, the product was built from the ground up, making it one of only a few purpose-built SFDR data solutions in the market. In effect since March 2021, SFDR introduces disclosure requirements on a set of Principle Adverse Impact (PAI) indicators, which outline the environmental, social and governance (ESG) factors that lead to adverse sustainability impacts. PAI disclosures will become mandatory for all financial market participants, including advisers, from 2022 as part of the EU’s strategy to combat greenwashing and incentivize funding of green projects. “We are committed to advancing sustainability objectives and providing essential data that market participants can rely on,” said Sabine Lochmann, Global Head of Moody’s

Piper Sandler Advises EverArc on its Acquisition of Perimeter Solutions16.6.2021 16:18:00 CEST | Press release

Piper Sandler & Co. chemicals & materials investment banking group (The Valence Group) has advised EverArc Holdings on its announced acquisition of 100% of Perimeter Solutions from SK Capital. EverArc Holdings Limited (LSE: EVRA / EVWA) has entered into a definitive agreement with SK Invictus Holdings S.à.r.l. an affiliate of funds advised by SK Capital Partners, to acquire 100% of SK Invictus Intermediate S.à.r.l., the ultimate parent company of Perimeter Solutions, a leading global manufacturer of high-quality firefighting products and lubricant additives, for total consideration of approximately $2 billion, consisting of cash and preferred shares, subject to customary closing conditions. The transaction is expected to close in Q4 2021. EverArc Holdings Limited (LSE: EVRA / EVWA) is a publicly-listed acquisition company that was formed in November 2019 to undertake an acquisition of a target company or business. Perimeter is a leading global manufacturer of high-quality firefighting

UVD Robots Selected by Global Facility Management Company ISS to Provide Autonomous Disinfection Robots16.6.2021 15:02:00 CEST | Press release

Today, Blue Ocean Robotics the manufacturer of UVD Robots for autonomous UV-C disinfection announced that it was selected by ISS World Services, a world leading global workplace experience and facility management company, to provide autonomous robots for disinfection as part of ISS’ global offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005504/en/ UVD Robots are helping to ensure outstanding cleaning and disinfection excellence. Unlike many stationary disinfection systems, the UVD Robot is a mobile, fully autonomous robot integrating UV-C light to disinfect against all known bacteria and viruses including Covid-19 not only on surfaces, but the air as well, providing a fully comprehensive infection control and prevention solution. UVD Robots enable facilities to reduce disease transmission by eliminating 99.99 percent of bacteria and viruses in any room. The robots have been rolled out to more than 70 countries

Auth0 Releases State of Secure Identity Report, Highlighting the Most Pervasive Threats to Digital Identities16.6.2021 15:01:00 CEST | Press release

Auth0, the modern identity platform, today announced the launch of its inaugural security report: The State of Secure Identity. This detailed report highlights key areas of concern for security professionals responsible for managing digital identities, including the exponential rise of credential stuffing attacks (automated attempts to compromise a large number of user accounts with stolen credentials), fraudulent registrations, and the widespread use of breached credentials. Recent headlines and high-profile cyber attacks give today’s security professionals a wide swath of serious threats to worry about. The primary goal of cybercriminal activity is to access critical resources, systems, and personal data, yet systems that can be put into place to minimize the risk of attack — like identity management — often get deprioritized. Lack of budget, resourcing, or attention on managing digital identities give threat actors a prime opportunity to take advantage of these discrepancies and sur